Pharmaceutical - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

176 to 200 of 305 results

Merck & Co and Gilead highlight new data at international HIV meeting

16-11-2012

US pharma giant Merck & Co (NYSE: MRK)presented new data at the 11th International Congress on HIV and…

Anti-viralsBiotechnologyCompleraGilead SciencesIsentressMerck & CoPharmaceuticalResearchStribild

ViiV Healthcare's dolutegravir shows promise in hard-to-treat HIV patients

16-11-2012

ViiV Healthcare, and HIV/AIDS company jointly owned by GlaxoSmithKline (LSE: GSK), Pfizer (NYSE: PFE)…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalResearchShionogiViiV Healthcare

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand

13-11-2012

Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

Bristol-Myers daclatasvir combo achieves 94% response in hep C patients

13-11-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) has, for the first time, released Phase II data demonstrating…

Anti-viralsasunaprevirBMS-791325Bristol-Myers SquibbdaclatasvirPharmaceuticalResearch

Incivo plus peginterferon and ribavirin positive for co-infected hep C and HIV patients, says Janssen

12-11-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Infectious Diseases - Diagnostics BVBA presented…

Anti-viralsBiotechnologyIncivoJanssenJohnson & JohnsonPharmaceuticalResearch

EU approves label change for Bristol-Myer's Baraclude

06-11-2012

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the European Commission has approved a Baraclude…

Anti-viralsBaracludeBristol-Myers SquibbEuropePharmaceuticalRegulation

Revised terms for ViiV Healthcare and Shionogi HIV partnership

30-10-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer,…

Anti-viralsdolutegravirGlaxoSmithKlineMergers & AcquisitionsPfizerPharmaceuticalShionogiViiV Healthcare

BioCryst and Presidio to merge, creating new competitor in HCV arena

22-10-2012

USA drugmaker BioCryst Pharmaceuticals (Nasdaq: BCRX) has signed a definitive accord to acquire privately…

Anti-viralsBioCryst PharmaceuticalsMergers & AcquisitionsPharmaceuticalPresidio Pharmaceuticals

US FDA agrees to review Sanofi Pasteur's new quadrivalent influenza vaccine

18-10-2012

Sanofi Pasteur, the vaccines division of Sanofi (Euronext: SAN) says it has filed a supplemental Biologics…

Anti-viralsNorth AmericaPharmaceuticalRegulationSanofiSanofi PasteurVaccines

Merck & Co in-licenses portfolio targeting HCMV from AiCuris for up to $570 million

16-10-2012

US pharma giant Merck & Co (NYSE: MRK) has entered into an exclusive worldwide licensing agreement with…

AiCurisAnti-viralsletermovirLicensingMerck & CoPharmaceutical

Abbott Lab's HCV regimen achieves near complete cure rates in mid-stage trial

16-10-2012

USA-based Abbott Laboratories (NYSE ABT) announced strong initial results from "Aviator," a Phase IIb…

Abbott LaboratoriesAnti-viralsPharmaceuticalResearch

Indonesian government overrides patents on seven HIV and hepatitis drugs

15-10-2012

In a move that was announced in early September but which just came to light last week, the government…

Anti-viralsGenericsPatentsPharmaceuticalPoliticsPricing

Australia's Benitec to acquire US RNAi firm Tacere

15-10-2012

Australia-based Benitec Biopharma (ASX: BLT) said last Friday that it has executed an agreement to acquire…

Anti-viralsBenitec BiopharmaBiotechnologyMergers & AcquisitionsPharmaceuticalTacere Therapeutics

Gilead's Truvada as HIV prevention to carry stronger FDA warning label

14-10-2012

The USA-based non-profit HIV/AIDS advocacy AIDS Healthcare Foundation (AHF) welcomed the news yesterday…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationTruvada

HIV drug nelfinavir shows efficacy in mouse models of HER2+ breast cancer

08-10-2012

The HIV protease inhibitor nelfinavir, marketed by Swiss drug major Roche as Viracept, can be used to…

Anti-viralsnelfinavirOncologyPharmaceuticalResearchRocheViracept

Achillion Pharma moves up as a contender in the HCV market, GlobalData believes

02-10-2012

On September 27, Achillion Pharmaceuticals (Nasdaq: ACHN) released news of positive results surrounding…

ACH-3102Achillion PharmaceuticalsAnti-viralsBiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Astellas to use Abbott's CMV assay for vaccine trial

06-09-2012

US health care major Abbott Laboratories (NYSE: ABT) says that it has signed an agreement to collaborate…

Abbott LaboratoriesAnti-viralsAstellas PharmaPharmaceuticalResearchTransVaxVaccines

Bristol-Myers drops hep C pill on patient safety issues

24-08-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) has discontinued development of BMS-986094 (formerly known…

Anti-viralsBiotechnologyBMS-986094Bristol-Myers SquibbPharmaceuticalRegulationResearch

NanoViricides' flu drug candidates demonstrate oral effectiveness

21-08-2012

US drug developer NanoViricides (OTCBB: NNVC) says that anti-influenza drug candidates under its FluCide…

Anti-viralsFluCideNanoViricidesPharmaceuticalResearchTamiflu

AHF calls for Gilead's Quad HIV pill to be put on "prior authorization" status

19-08-2012

In what may be an unprecedented move on drug pricing and access, advocates from the AIDS Healthcare Foundation…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalPricingQuadRegulation

176 to 200 of 305 results

Back to top